What is CRISPR Therapeutics's net investment in lease?

CRISPR Therapeutics (CRSP) reported net investment in lease of $128.67M in Q1 2026.

How has CRISPR Therapeutics's net investment in lease changed year-over-year?

CRISPR Therapeutics's net investment in lease decreased by 8.3% year-over-year, from $140.28M to $128.67M.

What is the long-term trend for CRISPR Therapeutics's net investment in lease?

Over 5 years (2020 to 2025), CRISPR Therapeutics's net investment in lease has grown at a 21.0% compound annual growth rate (CAGR), from $50.87M to $131.72M.

CRISPR Therapeutics CRSP Net Investment in Lease

Net Investment in Lease at other companies

CG OncologyCGON

——

Cogent Biosciences, Inc.COGT

——

Arrowhead ResearchARWR

——

BridgeBio PharmaBBIO

——

Krystal Biotech, Inc.KRYS

——

RevvityRVTY

——

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's net investment in lease?: CRISPR Therapeutics (CRSP) reported net investment in lease of $128.67M in Q1 2026.
How has CRISPR Therapeutics's net investment in lease changed year-over-year?: CRISPR Therapeutics's net investment in lease decreased by 8.3% year-over-year, from $140.28M to $128.67M.
What is the long-term trend for CRISPR Therapeutics's net investment in lease?: Over 5 years (2020 to 2025), CRISPR Therapeutics's net investment in lease has grown at a 21.0% compound annual growth rate (CAGR), from $50.87M to $131.72M.